

Autologous Cell Therapy-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/A76B7C36AD70EN.html>

Date: April 2018

Pages: 154

Price: US\$ 3,480.00 (Single User License)

ID: A76B7C36AD70EN

Abstracts

Report Summary

Autologous Cell Therapy-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Autologous Cell Therapy industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Autologous Cell Therapy 2013-2017, and development forecast 2018-2023

Main market players of Autologous Cell Therapy in EMEA, with company and product introduction, position in the Autologous Cell Therapy market

Market status and development trend of Autologous Cell Therapy by types and applications

Cost and profit status of Autologous Cell Therapy, and marketing status

Market growth drivers and challenges

The report segments the EMEA Autologous Cell Therapy market as:

EMEA Autologous Cell Therapy Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA Autologous Cell Therapy Market: Product Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Bone Marrow
Epidermis

EMEA Autologous Cell Therapy Market: Application Segment Analysis (Consumption
Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Neurology
Orthopedics
Cancer
Wound Healing
CVD
Autoimmune
Others

EMEA Autologous Cell Therapy Market: Players Segment Analysis (Company and
Product introduction, Autologous Cell Therapy Sales Volume, Revenue, Price and
Gross Margin):

BioTime, Inc.
BrainStorm Cell Therapeutics
Caladrius Biosciences, Inc.
Fibrocell Science, Inc.
Opexa Therapeutics, Inc.
Pharmicell Co., Inc.
Regeneus Ltd.
TiGenix NV
TxCell SA
U.S. Stem Cell, Inc.
Vericel Corporation

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF AUTOLOGOUS CELL THERAPY

- 1.1 Definition of Autologous Cell Therapy in This Report
- 1.2 Commercial Types of Autologous Cell Therapy
 - 1.2.1 Bone Marrow
 - 1.2.2 Epidermis
- 1.3 Downstream Application of Autologous Cell Therapy
 - 1.3.1 Neurology
 - 1.3.2 Orthopedics
 - 1.3.3 Cancer
 - 1.3.4 Wound Healing
 - 1.3.5 CVD
 - 1.3.6 Autoimmune
 - 1.3.7 Others
- 1.4 Development History of Autologous Cell Therapy
- 1.5 Market Status and Trend of Autologous Cell Therapy 2013-2023
 - 1.5.1 EMEA Autologous Cell Therapy Market Status and Trend 2013-2023
 - 1.5.2 Regional Autologous Cell Therapy Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Autologous Cell Therapy in EMEA 2013-2017
- 2.2 Consumption Market of Autologous Cell Therapy in EMEA by Regions
 - 2.2.1 Consumption Volume of Autologous Cell Therapy in EMEA by Regions
 - 2.2.2 Revenue of Autologous Cell Therapy in EMEA by Regions
- 2.3 Market Analysis of Autologous Cell Therapy in EMEA by Regions
 - 2.3.1 Market Analysis of Autologous Cell Therapy in Europe 2013-2017
 - 2.3.2 Market Analysis of Autologous Cell Therapy in Middle East 2013-2017
 - 2.3.3 Market Analysis of Autologous Cell Therapy in Africa 2013-2017
- 2.4 Market Development Forecast of Autologous Cell Therapy in EMEA 2018-2023
 - 2.4.1 Market Development Forecast of Autologous Cell Therapy in EMEA 2018-2023
 - 2.4.2 Market Development Forecast of Autologous Cell Therapy by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole EMEA Market Status by Types

- 3.1.1 Consumption Volume of Autologous Cell Therapy in EMEA by Types
- 3.1.2 Revenue of Autologous Cell Therapy in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in Europe
 - 3.2.2 Market Status by Types in Middle East
 - 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Autologous Cell Therapy in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Autologous Cell Therapy in EMEA by Downstream Industry
- 4.2 Demand Volume of Autologous Cell Therapy by Downstream Industry in Major Countries
 - 4.2.1 Demand Volume of Autologous Cell Therapy by Downstream Industry in Europe
 - 4.2.2 Demand Volume of Autologous Cell Therapy by Downstream Industry in Middle East
 - 4.2.3 Demand Volume of Autologous Cell Therapy by Downstream Industry in Africa
- 4.3 Market Forecast of Autologous Cell Therapy in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF AUTOLOGOUS CELL THERAPY

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Autologous Cell Therapy Downstream Industry Situation and Trend Overview

CHAPTER 6 AUTOLOGOUS CELL THERAPY MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

- 6.1 Sales Volume of Autologous Cell Therapy in EMEA by Major Players
- 6.2 Revenue of Autologous Cell Therapy in EMEA by Major Players
- 6.3 Basic Information of Autologous Cell Therapy by Major Players
 - 6.3.1 Headquarters Location and Established Time of Autologous Cell Therapy Major Players
 - 6.3.2 Employees and Revenue Level of Autologous Cell Therapy Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 AUTOLOGOUS CELL THERAPY MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 BioTime, Inc.

7.1.1 Company profile

7.1.2 Representative Autologous Cell Therapy Product

7.1.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of BioTime, Inc.

7.2 BrainStorm Cell Therapeutics

7.2.1 Company profile

7.2.2 Representative Autologous Cell Therapy Product

7.2.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of BrainStorm Cell Therapeutics

7.3 Caladrius Biosciences, Inc.

7.3.1 Company profile

7.3.2 Representative Autologous Cell Therapy Product

7.3.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Caladrius Biosciences, Inc.

7.4 Fibrocell Science, Inc.

7.4.1 Company profile

7.4.2 Representative Autologous Cell Therapy Product

7.4.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Fibrocell Science, Inc.

7.5 Opexa Therapeutics, Inc.

7.5.1 Company profile

7.5.2 Representative Autologous Cell Therapy Product

7.5.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Opexa Therapeutics, Inc.

7.6 Pharmicell Co., Inc.

7.6.1 Company profile

7.6.2 Representative Autologous Cell Therapy Product

7.6.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Pharmicell Co., Inc.

7.7 Regeneus Ltd.

7.7.1 Company profile

7.7.2 Representative Autologous Cell Therapy Product

7.7.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Regeneus Ltd.

7.8 TiGenix NV

7.8.1 Company profile

7.8.2 Representative Autologous Cell Therapy Product

7.8.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of TiGenix NV

7.9 TxCell SA

7.9.1 Company profile

7.9.2 Representative Autologous Cell Therapy Product

7.9.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of TxCell SA

7.10 U.S. Stem Cell, Inc.

7.10.1 Company profile

7.10.2 Representative Autologous Cell Therapy Product

7.10.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of U.S. Stem Cell, Inc.

7.11 Vericel Corporation

7.11.1 Company profile

7.11.2 Representative Autologous Cell Therapy Product

7.11.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Vericel Corporation

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF AUTOLOGOUS CELL THERAPY

8.1 Industry Chain of Autologous Cell Therapy

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF AUTOLOGOUS CELL THERAPY

9.1 Cost Structure Analysis of Autologous Cell Therapy

9.2 Raw Materials Cost Analysis of Autologous Cell Therapy

9.3 Labor Cost Analysis of Autologous Cell Therapy

9.4 Manufacturing Expenses Analysis of Autologous Cell Therapy

CHAPTER 10 MARKETING STATUS ANALYSIS OF AUTOLOGOUS CELL THERAPY

10.1 Marketing Channel

10.1.1 Direct Marketing

- 10.1.2 Indirect Marketing
- 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference

I would like to order

Product name: Autologous Cell Therapy-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/A76B7C36AD70EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A76B7C36AD70EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970